48 related articles for article (PubMed ID: 36853791)
1. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
[TBL] [Abstract][Full Text] [Related]
2. ARID1 and BRG1 Expression in Endometrial Cancer.
Kontomanolis EN; Symeonidis P; Nikolettos K; Perros P; Rody A; Tsikouras P; Nikolettos N; Giatromanolaki A
In Vivo; 2024; 38(3):1260-1265. PubMed ID: 38688602
[TBL] [Abstract][Full Text] [Related]
3. ARID1A loss activates MAPK signaling via DUSP4 downregulation.
Mandal J; Yu ZC; Shih IM; Wang TL
J Biomed Sci; 2023 Dec; 30(1):94. PubMed ID: 38071325
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic alterations in precursor lesions of endometrial endometrioid carcinoma.
Gotoh O; Sugiyama Y; Tonooka A; Kosugi M; Kitaura S; Minegishi R; Sano M; Amino S; Furuya R; Tanaka N; Kaneyasu T; Kumegawa K; Abe A; Nomura H; Takazawa Y; Kanao H; Maruyama R; Noda T; Mori S
J Pathol; 2024 Jul; 263(3):275-287. PubMed ID: 38734880
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiated Ovarian Carcinoma with ARID1A and ARID1B Mutations: A Clinicopathological Report and Literature Review.
Kamal M; Atwi D; Pang H; Li S; Hassell L
Int J Surg Pathol; 2023 Dec; 31(8):1526-1531. PubMed ID: 36843546
[TBL] [Abstract][Full Text] [Related]
6. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
Yang S; Jia Y; Liu X; Winters C; Wang X; Zhang Y; Devor EJ; Hovey AM; Reyes HD; Xiao X; Xu Y; Dai D; Meng X; Thiel KW; Domann FE; Leslie KK
Oncotarget; 2014 Oct; 5(20):9783-97. PubMed ID: 25229191
[TBL] [Abstract][Full Text] [Related]
7. Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.
Xing B; Zhang X; Gu X; Xiang L; Wang C; Jin Y
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17529-17541. PubMed ID: 37906351
[TBL] [Abstract][Full Text] [Related]
8. Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient.
Reid K; Camacho-Vanegas O; Pandya D; Camacho SC; Qiao RF; Kalir T; Padron-Rhenals MM; Beddoe AM; Dottino P; Martignetti JA
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37848227
[TBL] [Abstract][Full Text] [Related]
9. Integrated histological parameters define prognostically relevant groups in atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia.
Raffone A; Insabato L; Raimondo D; Del Piano I; Ricciardiello M; Cretella P; Neola D; Arciuolo D; Santoro A; Seracchioli R; Guida M; Travaglino A; Zannoni GF
Int J Gynecol Cancer; 2024 May; ():. PubMed ID: 38719279
[TBL] [Abstract][Full Text] [Related]
10. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
Gibson WJ; Hoivik EA; Halle MK; Taylor-Weiner A; Cherniack AD; Berg A; Holst F; Zack TI; Werner HM; Staby KM; Rosenberg M; Stefansson IM; Kusonmano K; Chevalier A; Mauland KK; Trovik J; Krakstad C; Giannakis M; Hodis E; Woie K; Bjorge L; Vintermyr OK; Wala JA; Lawrence MS; Getz G; Carter SL; Beroukhim R; Salvesen HB
Nat Genet; 2016 Aug; 48(8):848-55. PubMed ID: 27348297
[TBL] [Abstract][Full Text] [Related]
11. Exploring the role of macrophages in the progression from atypical hyperplasia to endometrial carcinoma through single-cell transcriptomics and bulk transcriptomics analysis.
Song X; Na R; Peng N; Cao W; Ke Y
Front Endocrinol (Lausanne); 2023; 14():1198944. PubMed ID: 37780629
[TBL] [Abstract][Full Text] [Related]
12. EZH2 inhibition in
Alldredge JK; Eskander RN
Gynecol Oncol Res Pract; 2017; 4():17. PubMed ID: 29093822
[TBL] [Abstract][Full Text] [Related]
13. Relevance of
De Leo A; Ravegnini G; Musiani F; Maloberti T; Visani M; Sanza V; Angelini S; Perrone AM; De Iaco P; Corradini AG; Rosini F; Grillini M; Santini D; Ceccarelli C; Zamagni C; Tallini G; de Biase D
Diagnostics (Basel); 2022 Feb; 12(3):. PubMed ID: 35328145
[TBL] [Abstract][Full Text] [Related]
14. Lesions sub-diagnostic of endometrioid intra-epithelial neoplasia/atypical hyperplasia: value of morphology and immunohistochemistry in predicting neoplastic outcome.
Wyvekens N; Mutter GL; Nucci MR; Kolin DL; Parra-Herran C
Histopathology; 2024 May; ():. PubMed ID: 38785042
[TBL] [Abstract][Full Text] [Related]
15. Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice.
Vistein R; Winer B; Myers S; Liberto J; Ishiyama S; Guo X; Saeki H; Wang TL; Shih IM; Gabrielson K
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36876944
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 Targeting Reveals a Significant Suppression of Tumorigenesis in Murine Endometrial Cancer with Pten Mutation.
Dunston K; Hunter MI; Johannesen E; Jung JS; Kim TH; Yoo JY; Jeong JW
Reprod Sci; 2024 Apr; ():. PubMed ID: 38637476
[TBL] [Abstract][Full Text] [Related]
17. Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer.
Li Y; Zhou W; Meng X; Murray SD; Li L; Fronk A; Lazaro-Camp VJ; Wen KK; Wu M; Dupuy A; Leslie KK; Yang S
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230806
[TBL] [Abstract][Full Text] [Related]
18. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
19. Early detection of endometrial cancer.
Ge J; Fader AN; Dudley JC
Gynecol Oncol; 2023 Jul; 174():A1-A2. PubMed ID: 37356825
[No Abstract] [Full Text] [Related]
20. ARID1A in Gynecologic Precancers and Cancers.
Morgan JE; Jaferi N; Shonibare Z; Huang GS
Reprod Sci; 2024 May; ():. PubMed ID: 38740655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
